PICO Description Population Patients with type 2 diabetes and chronic kidney disease, defined by an estimated glomerular filtration rate (eGFR)…
Browsing: Semaglutide
Summary: In patients with obesity-related heart failure with preserved ejection fraction (HFpEF) enrolled in the STEP-HFpEF trials (n=1,145), weekly semaglutide…
Summary: In 1,879 adults with type 2 diabetes participating in the SURPASS-2 phase 3 trial conducted across 128 sites in…
Summary: In overweight or obese adults with type 2 diabetes (T2DM) and non-alcoholic fatty liver disease (NAFLD), combination therapy of…
Summary: In adults aged 18 years or older with obesity-related heart failure with preserved ejection fraction (HFpEF), characterized by a…
Summary: In patients with heart failure with preserved ejection fraction, obesity (BMI ≥30), and type 2 diabetes, once-weekly semaglutide (2.4…
In patients with uncontrolled type 2 diabetes on metformin, once-weekly semaglutide 1.0 mg and once-daily canagliflozin 300 mg significantly improved…
In patients with type 2 diabetes treated with metformin and basal insulin, once-weekly semaglutide significantly improved glycaemic control (HbA1c reduction)…
In adults with type 2 diabetes inadequately controlled with metformin, semaglutide 1.0 mg once weekly significantly reduced HbA1c and body…
In patients with obesity and knee osteoarthritis, once-weekly semaglutide (2.4 mg) significantly reduced body weight and pain compared to placebo, though it was associated with gastrointestinal side effects.